Research output per year
Research output per year
Search results
-
2023
PII-059* Mechanistic Population Pharmacokinetic Modeling of Risdiplam for Extrapolation of Exposure and Cyp3a Drug-drug Interaction in Neonates with Spinal Muscular Atrophy
Cleary, Y., Kletzl, H., Grimsey, P., Heinig, K., Ogungbenro, K., Silber--Baumann, H., Frey, N., Aarons, L., Galetin, A. & Gertz, M., 1 Mar 2023, In: Clinical Pharmacology & Therapeutics. 113, p. S63 1 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
2022
Estimation of in Vivo Fmo3 Ontogeny By Mechanistic Population Pharmacokinetic Modeling of Risdiplam in Infants, Children and Adults with Spinal Muscular Atrophy.
Cleary, Y., Kletzl, H., Grimsey, P., Ogungbenro, K., Aarons, L., Galetin, A. & Gertz, M., Mar 2022, In: Clinical Pharmacology & Therapeutics. 111, p. S70-S70 1 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
2021
Application of Coproporphyrin I Pbpk Model to Evaluate the Impact of Slco1b1 Genotype, Ethnicity, and Sex on Its Oatp1b-mediated Interactions.
Takita, H., Barnett, S., Zhang, Y., Menochet, K., Shen, H., Ogungbenro, K. & Galetin, A., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S83-S83 1 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
Model-based Investigation of Cyp3a Enzyme Inactivation Effect of Risdiplam in Infants, Children, and Adults with Spinal Muscular Atrophy (sma).
Cleary, Y., Gertz, M., Grimsey, P., Guenther, A., Heinig, K., Ogungbenro, K., Aarons, L., Galetin, A. & Kletzl, H., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S9-S10 2 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
Parent-metabolite Physiologically-based Pharmacokinetic/pharmacodynamic (pbpk/pd) Modelling Using Ivabradine, a Cyp3a4 Substrate: Ddi Risk Evaluation in Children.
Lang, J., Vincent, L., Marylore, C., Ogungbenro, K. & Galetin, A., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S14-S14 1 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
Population and Physiologically-based Pharmacokinetic Modeling of Risdiplam in Infants, Children, and Adults with Spinal Muscular Atrophy (sma).
Cleary, Y., Kletzl, H., Grimsey, P., Frey, N., Baumann, H., Stillhart, C., Poirier, A., Heinig, K., Fowler, S., Ogungbenro, K., Aarons, L., Galetin, A. & Gertz, M., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S10-S10 1 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
Population Pharmacokinetic Modeling and Simulation to Support Qualification of Fatty Acids Tetradecanedioate As Endogenous Probe for Oatp1b1 Transporter.
Ahmad, A., Takita, H., Ogungbenro, K. & Galetin, A., Mar 2021, In: Clinical Pharmacology & Therapeutics. 109, p. S69-S70 2 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
2018
The impact of lysosomal sequestration on desipramine cellular disposition and metabolic drug-drug interactions in rat and human hepatocytes
Ufuk, A., Matsunaga, N., Hallifax, D. & Galetin, A., 12 Jan 2018, In: Drug Metabolism and Pharmacokinetics. 33, 1, p. S46 1 p., P77.Research output: Contribution to journal › Meeting Abstract